ESCMID weekly news 18.10.2022


 

WEEKLY NEWS

18 October 2022

Submit your ECCMID abstract

Submission for Regular Abstracts, Case reports and the new TAE Research Bites opened on October 17th. Every year ECCMID accepts hundreds of abstracts in the form of oral or poster presentations, after the review by the panel of experts. While submitting the abstract, you can apply for our grants supporting participation at ECCMID.

IMPORTANT DATES AND DEADLINES

20 October 2022 | Deadline

Funded Observerships →

9-10 February 2023 | Course

Antifungal stewardship from primary to tertiary care →

17-19 March 2023 | Course

Antimicrobial stewardship (AMS) in migration- and travel-associated infections →



Call of applications for funded Observerships closing in two days!

The call for 50 funded ESCMID observerships closes on 20 October 2022. For next visits, travel funds have been increased for inter-continental visits, to help support our observers. Don’t miss the chance to perform outstanding work in renowned centres and enrich your career.




Register for the International Congress of Infectious Diseases

The International Congress on Infectious Diseases 2022 features an expanded range of sessions by bringing the One Health aspect to the world of clinical infectious diseases and microbiology.




CMI Readership survey

CMI Readership survCMI, the official journal of ESCMID, is hosting a survey to better address the needs of readers. This short survey allows us to create a journal which best fits audience expectations, making CMI more beneficial for everyone.




Public consultation on ESCMID/EUCIC clinical guidelines

Public consultation phase is open for ESCMID/EUCIC Clinical guidelines on antibiotic surgical prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery.



A risk score for identifying patients at low risk for bacterial meningitis in adults with CSF leukocytosis and a negative Gram stain →

EMA recommends standard marketing authorisations for Comirnaty and Spikevax COVID-19 vaccines →



Positive recommendation on marketing authorisation
for a new medicine (maribavir)
to treat cytomegalovirus (CMV) infections →

Register for ESCMID Courses and Workshops →



ESCMID Executive Office
Gerbergasse 14
4001 Basel
Switzerland

Phone +41 61 508 0150
info@escmid.org
www.escmid.org





The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.



Nahoru